Search for Clinical Trial Results
Anaplastic Large Cell Lymphoma - 340 Studies Found
Status | Study |
Completed |
Study Name: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Condition: Large Cell Lymphoma Date: 2004-12-10 Interventions: Drug: SGN-30 |
Recruiting |
Study Name: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Condition: Anaplastic Large Cell Lymphoma, ALK-Positive Date: 2015-04-03 Interventions: Drug: crizotinib |
Withdrawn |
Study Name: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma Condition: Lymphoma, Large-Cell Date: 2006-03-01 Interventions: Drug: MDX-060 |
Active, not recruiting |
Study Name: Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Condition:
|
Completed |
Study Name: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Condition:
Date: 2009-03-19 Interventions: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
Recruiting |
Study Name: Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + Condition: ALCL Date: 2016-09-07 Interventions: Other: Blood sample |
Recruiting |
Study Name: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Condition:
Date: 2016-10-18 Interventions: Drug: Brentuximab Vedotin Brentuximab vedotin IV infusion. |
Completed |
Study Name: Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma Condition: Lymphoma Date: 1999-11-01 Interventions: Biological: monoclonal antibody HeFi-1 |
Recruiting |
Study Name: AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Condition:
|
Withdrawn |
Study Name: Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Condition:
|